Trial Profile
Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 08 Jun 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 08 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Oct 2010 New trial record